Dillard's Swings To Profit In Q2 - Quick Facts

Luxury department store chain Dillard's, Inc. (DDS) reported Thursday a second-quarter net income of $185.7 million or $8.81 per share, compared to a net loss of $8.6 million or $0.37 per share in the prior-year quarter.

Net sales for the quarter surged 72% to $1.57 billion from $919.0 million in the same quarter last year.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.54 per share on net sales of $1.31 billion for the quarter. Analysts' estimates typically exclude special items.

Comparable store retail sales for the second quarter of 2021 compared to the second quarter of 2019 increased 14%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT